FDA leadership faces potential shake-up while medical breakthroughs emerge in stroke prevention, rare disease treatment, and diagnostic innovations

The White House has approved a plan to fire FDA Commissioner Marty Makary, signaling a significant leadership change at the nation's top drug regulatory agency.

The OCEANIC-STROKE trial demonstrates that the investigational Factor XIa inhibitor asundexian reduces recurrent ischemic stroke risk and decreases stroke severity when they occur, offering a new prevention strategy.

NICE recommended givinostat for all types of Duchenne Muscular Dystrophy, potentially delaying disease progression by up to 5 years for approximately 530 patients in the UK.

A cruise ship hantavirus outbreak has prompted WHO officials to rapidly develop containment guidance as the vessel heads to Tenerife, marking the first known ship-borne spread of this virus.

Gastric sleeve endoscopy continues to promote significant weight loss after GLP-1 therapy discontinuation, offering a minimally invasive alternative for sustained weight management.

Combined genetic risk scores show promise in identifying individuals at high risk for eight cardiovascular conditions, improving upon current clinical risk prediction tools.

A new blood test measuring basophil activation markers accurately identifies sesame seed allergy in children with greater precision than traditional skin prick and standard blood tests.

Early antiviral prophylaxis with oseltamivir administered to 70% or more of nursing home residents within 48 hours of outbreak onset significantly reduces hospitalizations, though German logistics may impede rapid deployment.